文献速递免疫规划传染病防控与疫情报告

既往接种ACWY群脑膜炎球菌疫苗者中的A、C、W、Y群脑膜炎球菌病——美国,2014-2018年

Serogroup A, C, W, and Y meningococcal disease in persons previously vaccinated with a serogroup ACWY meningococcal vaccine - United States, 2014-2018.
PubMed 文献 · Vaccine · 2021-11-19

分析美国2014-2018年NNDSS报告的822例A、C、W、Y群脑膜炎球菌病,其中34例(4%)既往接种过至少1剂MenACWY疫苗。免疫抑制、接种不完整和免疫力减弱可能促成突破性病例;需持续监测。

要点

  • 34例接种过MenACWY疫苗者中,17例(50%)发生在最近一剂后超过3年。
  • 接种者中HIV感染者比例显著高于未接种者。
  • 接种者与未接种者的病例致死率无差异。

核心结论

  • 免疫抑制、接种不完整和免疫力减弱可能促成了已接种MenACWY疫苗者的脑膜炎球菌病突破性病例。
  • 持续监测既往接种者的A、C、W、Y群脑膜炎球菌病将有助于指导脑膜炎球菌病预防工作。

研究设计与样本

  • 分析2014年至2018年通过国家法定报告疾病监测系统(NNDSS)报告的A、C、W、Y群脑膜炎球菌病病例;州卫生部门提交危险因素和临床病程的补充信息。

主要发现

  • 2014-2018年NNDSS共报告822例A、C、W、Y群脑膜炎球菌病,其中34例(4%)为既往接种过至少1剂MenACWY疫苗的患者。
  • 23例接种患者按建议为最新接种状态,7例未达最新状态,4例缺少接种剂次信息。
  • 17例(50%)发生在最近一剂后超过3年。
  • 接种患者中HIV感染者比例显著高于未接种患者。
  • 34例接种患者中8例存在免疫抑制,包括5例HIV感染者、1例使用依库珠单抗、2例使用其他免疫抑制药物。

关键数值与推荐

  • 免疫实践咨询委员会(ACIP)建议在11-12岁常规接种四价ACWY群脑膜炎球菌结合疫苗,16岁接种加强剂。
  • ACIP还建议脑膜炎球菌病风险增加者接种脑膜炎球菌疫苗,包括因基础疾病风险增加者接种2剂基础系列和定期加强剂。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Advisory Committee on Immunization Practices (ACIP) recommends routine vaccination with a quadrivalent meningococcal conjugate serogroup A,C,W,Y (MenACWY) vaccine at 11-12 years of age, with a booster dose at 16 years. ACIP also recommends meningococcal vaccination for persons at increased risk of meningococcal disease, including a 2-dose primary series and regular booster doses for persons at increased risk because of underlying medical conditions. U.S. cases of serogroup A, C, W, and Y meningococcal disease in persons previously vaccinated with MenACWY vaccine have not been systematically described since 2008. Characterization of these cases is important to understand potential factors leading to breakthrough disease. METHODS: We analyzed cases of serogroup A,C,W, and Y meningococcal disease reported through the National Notifiable Diseases Surveillance System (NNDSS) from 2014 through 2018. State health departments submitted additional information on risk factors and clinical course. RESULTS: During 2014-2018, 822 cases of serogroup A, C, W, and Y meningococcal disease were reported through NNDSS; 34 (4%) were in patients who previously received ≥ 1 dose of MenACWY vaccine. Twenty-three vaccinated patients were up-to-date on MenACWY vaccine per recommendations, and seven were not up-to-date; four were missing information on the number of doses received. Seventeen cases (50%) occurred > 3 years after the most recent dose. A significantly higher proportion of vaccinated patients were people living with HIV (PLWH) compared to unvaccinated patients. Eight of the 34 vaccinated patients were immunosuppressed, including five PLWH, one taking eculizumab, and two taking other immunosuppressive medications. The case fatality ratio did not differ between vaccinated and unvaccinated patients. CONCLUSIONS: Immunosuppression, incomplete vaccination, and waning immunity likely contributed to breakthrough cases of meningococcal disease among people who received MenACWY vaccine. Continued monitoring of serogroup A, C, W, and Y meningococcal disease in previously vaccinated persons will help inform meningococcal disease prevention efforts.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Blain AE, Reese HE, Marjuki H, et al. Serogroup A, C, W, and Y meningococcal disease in persons previously vaccinated with a serogroup ACWY meningococcal vaccine - United States, 2014-2018. Vaccine. 2021. PMID: 34802785. doi:10.1016/j.vaccine.2021.11.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。